Agilent performed well in the fourth quarter and its revenues as well as earnings were vastly exceeding its forecasts as well as market expectations. Revenue for the Agilent CrossLab Group in the fourth quarter was $381 million. The Diagnostics and Genomics Group also reported sales of $352 million, an 8% core increase driven by the strong growth in the low 20s for NASD. Their genomics portfolio also demonstrated strong growth in the low teens, while pathology grew in the mid-single digits. They ....
01 Dec 2022
Agilent Technologies: Key Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (12/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Agilent Technologies: Key Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (12/22)
- Published:
01 Dec 2022 -
Author:
Ishan Majumdar -
Pages:
27
Agilent performed well in the fourth quarter and its revenues as well as earnings were vastly exceeding its forecasts as well as market expectations. Revenue for the Agilent CrossLab Group in the fourth quarter was $381 million. The Diagnostics and Genomics Group also reported sales of $352 million, an 8% core increase driven by the strong growth in the low 20s for NASD. Their genomics portfolio also demonstrated strong growth in the low teens, while pathology grew in the mid-single digits. They ....